Israeli digital health company GlucoMe announced Wednesday that its new Diabetes Decision Support System (DSS) has received a CE Mark, indicating that the technology conforms with health, safety, and environmental standards of the European Union.
The DSS is an algorithm-based software that provides real-time analysis of a patient with Type 2 Diabetes Mellitus (T2DM) to improve the care of T2DM patients. A DSS is an information system that facilitates decision-making for rapidly changing and unspecific problems.
GlucoMe’s DSS allows for personalized treatment recommendations, enabling timely drug intensification (second and third line) to patients. Despite guidelines mandating drug intensification within three to six months of initial treatment, it is often delayed, the company said, leading to poor diabetes management and health complications.
“Using the DSS will enable better diabetes control by ensuring each patient receives timely treatment, as well as reduce associated costs from diabetes complications,” GlucoMe’s CEO Yiftah Ben-Aharon said in a statement.
As well as its recent certification mark, the DSS technology’s algorithm is 100 percent compliant with internationally-recognized medication guidelines, such as those of the American Diabetes Association and the European Association for the Study of Diabetes.
“Receiving the CE mark is a major leap forward to realizing our vision of providing a smart, end-to-end digital platform that enables efficient and comprehensive diabetes management,” said Ben-Aharon. “Health care providers and physicians now have a valuable and practical tool that empowers their decision-making to better personalize T2DM patient treatment plans.”
GlucoMe’s diabetes management platform, which is on track to become fully autonomous, includes a wireless blood glucose monitor, a mobile app, a cloud-based monitoring, and control software for healthcare professionals, and a Control Tower alert system.
The announcement of GlucoMe’s CE Mark was made just months after it partnered with German multinational pharmaceuticals firm Merck in August 2018.